Projects in Clinical Development

Product

Indication

Clinical Phase

Approval

Marketed

III

Drugs on the market

Eligard^® 1)

Veregen^{® 2)}

Genital Warts

Drugs in clinical development

EndoTAG™-1

Pancreatic Cancer

Breast Cancer

Additional solid tumors

RhuDex^®

Rh. Arthritis

Chance of reaching the market³⁾

10-30%

30-60%

60-80%

80-90%

¹ European marketing rights acquired from Tolmar Inc.(formerly QLT, Inc.). Marketing partnership with Astellas Pharma Ltd.
² Marketing partnership with Nycomed for the US market, Juste S.A.Q.F., for Spain and Portugal, with Abbott (previously Solvay) for Germany, Austria and Switzerland, with Teva Pharmaceutical Industry Limited for Israel, with Meditrina Ltd. for Greece and Cyprus, with GC Rise Pharmaceutical Co. Ltd. for China and with JS BioPharm for South Korea.
³ Industrial average, source: Ernst&Young, 2009.